SCHEMBL25280277

SCHEMBL25280277

COc1cc(/C=C/C(=O)c2ccc(N3Cc4cc(C)c(C)cc4C3)cc2)ccc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCL12 P48061 10/20 0.66
▸ CXCR4 P61073 1/20 0.61
▸ FGFR1 P11362 1/20 0.57
▸ TUBB4A P04350 1/20 0.57
▸ TUBB P07437 1/20 0.57
▸ TUBA3C P0DPH7 1/20 0.57
▸ TUBA1B P68363 1/20 0.57
▸ TUBA4A P68366 1/20 0.57
▸ TUBB4B P68371 1/20 0.57
▸ TUBB3 Q13509 1/20 0.57
▸ TUBB2A Q13885 1/20 0.57
▸ TUBB8 Q3ZCM7 1/20 0.57
▸ TUBA3E Q6PEY2 1/20 0.57
▸ TUBA1A Q71U36 1/20 0.57
▸ TUBA1C Q9BQE3 1/20 0.57
▸ TUBB6 Q9BUF5 1/20 0.57
▸ TUBB2B Q9BVA1 1/20 0.57
▸ TUBB1 Q9H4B7 1/20 0.57
▸ ACHE P22303 1/20 0.56
▸ KDR P35968 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30383603 1.00 CXCL12 (0.66) CXCL12CXCR4FGFR1TUBB4ATUBB
SCHEMBL25203022 1.00 CXCL12 (0.66) CXCL12CXCR4FGFR1TUBB4ATUBB
SCHEMBL25184976 0.83 CTSL (0.64) CXCL12CTSLCTSBMEN1KMT2A
SCHEMBL25195214 0.83 CTSL (0.64) CXCL12CTSLCTSBMEN1KMT2A
SCHEMBL30383658 0.83 CTSL (0.64) CXCL12CTSLCTSBMEN1KMT2A
SCHEMBL30383316 0.83 CTSL (0.64) CXCL12CTSLCTSBMEN1KMT2A
SCHEMBL19782822 0.83 KDR (0.78) CXCL12CXCR4FGFR1ACHEKDR
SCHEMBL19782818 0.83 MAPT (0.67) CXCL12CXCR4FGFR1ACHEKDR
SCHEMBL25219790 0.83 MAPT (0.67) CXCL12CXCR4FGFR1ACHEKDR
SCHEMBL25193952 0.82 CXCL12 (0.89) CXCL12CXCR4TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 — — US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 — — US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B CXCL12 399/4885CXCR4 1201/4885FGFR1 2932/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 CXCL12 287/4885CXCR4 1725/4885FGFR1 4286/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 CXCL12 287/4885CXCR4 1725/4885FGFR1 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback